Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: May 7, 2025
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies
Read more at globenewswire.com
